Randomized phase II trial of irinotecan with paclitaxel or gemcitabine for non-small cell lung cancer: Association of UGT1A1*6 and UGT1A1*27 with severe neutropenia

Journal of Thoracic Oncology

Volumn 6, Issue 1, 2011, Pages 121-127

  Nakamura, Yoichi ^a   Soda, Hiroshi ^b   Oka, Mikio ^c   Kinoshita, Akitoshi ^d   Fukuda, Minoru ^e   Fukuda, Masaaki ^f   Takatani, Hiroshi ^f   Nagashima, Seiji ^b   Soejima, Yoshifumi ^g   Kasai, Takashi ^f   Nakatomi, Katsumi ^a   Masuda, Noriyuki ^h   Tsukamoto, Kazuhiro ⁱ   Kohno, Shigeru ^a  

^a NAGASAKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b Sasebo Shiritsu Sogo Hospital   (Japan)

^c KAWASAKI MEDICAL SCHOOL   (Japan)

^d NATIONAL HOSPITAL ORGANIZATION NAGASAKI MEDICAL CENTER   (Japan)

^e Nagasaki Municipal Hospital   (Japan)

^f JAPANESE RED CROSS NAGASAKI GENBAKU HOSPITAL   (Japan)

^g Ureshino Medical Center   (Japan)

^h KITASATO UNIVERSITY HOSPITAL   (Japan)

ⁱ NAGASAKI UNIVERSITY   (Japan)

Author keywords

Gemcitabine; Irinotecan; NSCLC; Paclitaxel; UGT1A1*27; UGT1A1*6

Indexed keywords

GEMCITABINE; GLUCURONOSYLTRANSFERASE; IRINOTECAN; PACLITAXEL;

ADULT; AGED; ARTICLE; CANCER GROWTH; CANCER STAGING; CANCER SURVIVAL; CONSTIPATION; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; FEBRILE NEUTROPENIA; FEMALE; GENETIC ASSOCIATION; HUMAN; LEUKOPENIA; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; NEUROPATHY; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT RESPONSE;

EID: 78651097801     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e318200e4e8     Document Type: Article

References (30)

1. Parkin DM. Global cancer statistics in the year 2000. Lancet Oncol 2001;2:533-543.
2. Schiller JH, Harrington D, Belani CP, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002;346:92-98.
3. Kubota K, Kawahara M, Ogawara M, et al. Vinorelbine plus gemcitabine followed by docetaxel versus carboplatin plus paclitaxel in patients with advanced non-small-cell lung cancer: a randomised, open-label, phase III study. Lancet Oncol 2008;9:1135-1142.
4. Olaussen KA, Dunant A, Fouret P, et al. DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med 2006;355:983-991.
5. Kawato Y, Aonuma M, Hirota Y, et al. Intracellular roles of SN-38, a metabolite of the camptothecin derivative CPT-11, in the antitumor effect of CPT-11. Cancer Res 1991;51:4187-4191.
6. Plunkett W, Huang P, Xu YZ, et al. Gemcitabine: metabolism, mechanisms of action, and self-potentiation. Semin Oncol 1995;22:3-10.
7. Kasai T, Oka M, Soda H, et al. Phase I and pharmacokinetic study of paclitaxel and irinotecan for patients with advanced non-small cell lung cancer. Eur J Cancer 2002;38:1871-1878.
8. Takatani H, Soda H, Nakamura Y, et al. Phase I study of irinotecan and gemcitabine in previously untreated patients with advanced non-small cell lung cancer. Jpn J Clin Oncol 2007;37:353-357.
9. Ando Y, Saka H, Ando M, et al. Polymorphisms of UDP- glucuronosyltransferase gene and irinotecan toxicity: a pharmacogenetic analysis. Cancer Res 2000;60:6921-6926.
10. Innocenti F, Undevia SD, Iyer L, et al. Genetic variants in the UDPglucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan. J Clin Oncol 2004;22:1382-1388.
11. O'Dwyer PJ, Catalano RB. Uridine diphosphate glucuronosyltransferase (UGT) 1A1 and irinotecan: practical pharmacogenomics arrives in cancer therapy. J Clin Oncol 2006;24:4534-4538.
12. Marcuello E, Altes A, Menoyo A, et al. UGT1A1 gene variations and irinotecan treatment in patients with metastatic colorectal cancer. Br J Cancer 2004;91:678-682.
13. Rouits E, Boisdron-Celle M, Dumont A, et al. Relevance of different UGT1A1 polymorphisms in irinotecan-induced toxicity: a molecular and clinical study of 75 patients. Clin Cancer Res 2004;10:5151-5159.
14. Saeki M, Saito Y, Jinno H, et al. Genetic polymorphisms of UGT1A6 in a Japanese population. Drug Metab Pharmacokinet 2005;20: 85-90.
15. Han JY, Lim HS, Shin ES, et al. Comprehensive analysis of UGT1A polymorphisms predictive for pharmacokinetics and treatment outcome in patients with non-small-cell lung cancer treated with irinotecan and cisplatin. J Clin Oncol 2006;24:2237-2244.
16. Yamamoto N, Takahashi T, Kunikane H, et al. Phase I/II pharmacokinetic and pharmacogenomic study of UGT1A1 polymorphism in elderly patients with advanced non-small cell lung cancer treated with irinotecan. Clin Pharmacol Ther 2009;85:149-154.
17. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92:205-216.
18. Shimizu T, Saijo N. [Common toxicity criteria: version 2.0, an improved reference for grading the adverse reaction of cancer treatment]. Nippon Rinsho 2003;61:937-942.
19. Simon R, Wittes RE, Ellenberg SS. Randomized phase II clinical trials. Cancer Treat Rep 1985;69:1375-1381.
20. Excoffier L, Slatkin M. Maximum-likelihood estimation of molecular haplotype frequencies in a diploid population. Mol Biol Evol 1995;12: 921-927.
21. Lewontin RC. On measures of gametic disequilibrium. Genetics 1988; 120:849-852.
22. Hill WG, Robertson A. The effects of inbreeding at loci with heterozygote advantage. Genetics 1968;60:615-628.
23. Chen S, Zhang J, Wang R, et al. The platinum-based treatments for advanced non-small cell lung cancer, is low/negative ERCC1 expression better than high/positive ERCC1 expression? A meta-analysis. Lung Cancer 2010;70:63-70.
24. Grossi F, Aita M, Defferrari C, et al. Impact of third-generation drugs on the activity of first-line chemotherapy in advanced non-small cell lung cancer: a meta-analytical approach. Oncologist 2009;14:497-510.
25. Watanabe H, Ieki R, Mori K, et al. Tumor response category for the indicator of prognosis: analysis of survival data in a four-arm cooperative study (FACS) for advanced non-small cell lung cancer (NSCLC). ASCO 2009:Abstr#8088.
26. Cohen MH, Gootenberg J, Keegan P, et al. FDA drug approval summary: bevacizumab (Avastin) plus Carboplatin and Paclitaxel as firstline treatment of advanced/metastatic recurrent nonsquamous non-small cell lung cancer. Oncologist 2007;12:713-718.
27. Saito Y, Maekawa K, Ozawa S, et al. Genetic polymorphisms and haplotypes of major drug metabolizing enzymes in East Asians and their comparison with other ethnic populations. Curr Pharmacogenomics 2007;5:49-78.
28. Ando Y, Fujita K, Sasaki Y, et al. UGT1AI*6 and UGT1A1*27 for individualized irinotecan chemotherapy. Curr Opin Mol Ther 2007;9: 258-262.
29. Minami H, Sai K, Saeki M, et al. Irinotecan pharmacokinetics/ pharmacodynamics and UGT1A genetic polymorphisms in Japanese: roles of UGT1A1*6 and *28. Pharmacogenet Genomics 2007;17:497-504.
30. Hoskins JM, Goldberg RM, Qu P, et al. UGT1A1*28 genotype and irinotecan-induced neutropenia: dose matters. J Natl Cancer Inst 2007; 99:1290-1295.